ReviewMarine drugs2026
Research Progress on Marine Active Substances in Improving Atherosclerosis.
Chenyang Xie, Jiapeng Qi, Wenmei Huang, Bei Chen, Min Xu, Shuji Liu, Yongchang Su, Yixiong Lin, Kun Qiao, Zhiyu Liu
Abstract readReview
In one paragraphReview in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Chenyang XieEngineering Technological Center of Mushroom Industry, School of Biological Science and Biotechnology, Minnan Normal University, Zhangzhou 363000, China.
Jiapeng QiKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.
Wenmei HuangXiamen Daozhiyuan Biological Technology Co., Ltd., Xiamen 361024, China.
Bei ChenKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.ORCID 0000-0002-9738-7568 Min XuKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.
Shuji LiuKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.ORCID 0000-0001-8058-2730 Yongchang SuKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.
Yixiong LinEngineering Technological Center of Mushroom Industry, School of Biological Science and Biotechnology, Minnan Normal University, Zhangzhou 363000, China.
Kun QiaoKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.ORCID 0000-0002-2372-2837 Zhiyu LiuKey Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, Fisheries Research Institute of Fujian, Xiamen 361013, China.
Funding
Key Laboratory of Cultivation and High-value Utilization of Marine Organisms in Fujian Province 20221jscq08Program for Promoting High-Quality Development of Marine and Fishery Industry in Fujian Provincestry in Fujian Province FJHYF -L-2023-23Science and Technology Project of Putian City 2024NJJ010the Basic Research Program for Provincial Public Welfare Research Institutes in Fujian Province 2024R1047
6 · The paper itselfAbstract
Atherosclerosis is the primary pathological foundation of various cardiovascular and cerebrovascular diseases. Although existing treatment strategies exhibit certain efficacy, they still encounter limitations such as pronounced side effects and a single-target approach. The oceans have nurtured a rich diversity of organisms, and the secondary metabolites they generate possess novel structures, diverse activities, and unique mechanisms of action, offering new prospects for the development of anti-atherosclerotic drugs. This paper reviews advancements related to research on marine-derived active substances that possess anti-atherosclerotic activity, as well as current challenges in research on active substances, with the objective of laying a foundation for the development of anti-atherosclerotic drugs.
Indexed as
Aquatic OrganismsAtherosclerosisBiological ProductsAnimalsHumansBiological Productsatherosclerosismarine-derived active substancesmolecular mechanism
Identifiers
PMID42188300
PMCPMC13208890
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390